Even though it is a large med-tech company with a market cap over $37 billion, Baxter International (NYSE: BAX ) just doesn't seem to garner all that much investor interest, or at least not as much as peers/rivals like Biogen Idec (NASDAQ: BIIB ) , Novo Nordisk (NYSE: NVO ) , CareFusion (NYSE: CFN ) , and Hospira (NYSE: HSP )
. Institutions pay attention, though, and investors may be in a good
position to benefit from their skepticism. While the Street is wrapped
up in trying to guess just how much business Baxter will lose in its
hemophilia and specialty pharmaceuticals businesses to competition, it
looks as though the market may be missing the forest for the trees.
Please continue here:
http://www.fool.com/investing/general/2013/12/26/baxter-international-the-street-is-too-negative-on.aspx
No comments:
Post a Comment